EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR-positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan.
Alpelisib;Fulvestrant
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR-positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan. ### Output: Alpelisib;Fulvestrant